BOY WAS MY INITIAL THINKING ON THE OFFERING WRONG!
Key notes from here: being offered at $9.75 a share!
Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers for the offering.
Reddit won’t let me post the link but it’s on their X and LinkedIn.
Damn just sent that out yesterday and it happened so quick, wonder if this fully derails stocks momentum for the next few weeks
Saw some X posts that there could be potential dilution to get funding + buffer for commercialization of ABCL635.
Didn’t get a chance to see the readout press conference and not plugged into financial games of biotech like that. I know there’s cash available already but is this a legit concern or just fear mongering?
To me they were optimistic and excited about the future.
Maybe it’s what I wanted to hear so I interpreted it that way?
if this trial fails I honestly would be shocked.
Monday can’t come fast enough
Anyone knowledgeable in biotech that has more insight?